• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Arvinas Inc

Can Arvinas, Inc. and Pfizer Inc. scale protein degradation in oncology markets

By Soujanya Ravi on May 1, 2026   Pharma & Biotech  

Can Arvinas, Inc. and Pfizer Inc. scale protein degradation in oncology markets

FDA approves VEPPANU, the first PROTAC therapy. Discover how Arvinas, Inc. is reshaping breast cancer treatment strategies today.

Recent Posts

  • Why 3Shape’s Dx Software clearance matters for digital dentistry’s next phase
  • FDA clears Olympus POWERSEAL Open Extended Jaw as surgical energy competition grows
  • Rezolute’s ersodetug data deepens the congenital hyperinsulinism regulatory debate
  • How Arvinas and Pfizer’s VEPPANU approval tests the commercial future of PROTAC drugs
  • Can Arvinas, Inc. and Pfizer Inc. scale protein degradation in oncology markets
  • Does Rhythm Pharmaceuticals, Inc. now lead the rare neuroendocrine obesity treatment space?
  • Is Noema Pharma AG building a multi-symptom menopause therapy platform with cendifensine?
  • Is BRC Therapeutics opening a new regulatory lane for cannabinoid-based CRPS therapies?
  • Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?
  • Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
  • What Orchestra BioMed Holdings, Inc.’s AVIM strategy reveals about the future of hypertension device innovation
  • Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes